Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
38.22
-0.01 (-0.03%)
At close: Mar 9, 2026, 4:00 PM EDT
38.20
-0.02 (-0.05%)
After-hours: Mar 9, 2026, 6:16 PM EDT
Crinetics Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 101.54 | 264.55 | 54.9 | 32.67 | 200.7 | Upgrade
|
| Short-Term Investments | 926.35 | 1,090 | 503.66 | 301.75 | 133.01 | Upgrade
|
| Cash & Short-Term Investments | 1,028 | 1,354 | 558.56 | 334.43 | 333.71 | Upgrade
|
| Cash Growth | -24.09% | 142.42% | 67.02% | 0.21% | 95.29% | Upgrade
|
| Accounts Receivable | 0.59 | - | - | - | - | Upgrade
|
| Other Receivables | - | - | 9.26 | 2.9 | 1.48 | Upgrade
|
| Receivables | 0.59 | - | 9.26 | 2.9 | 1.48 | Upgrade
|
| Inventory | 2.02 | - | - | - | - | Upgrade
|
| Prepaid Expenses | 17.84 | 20.82 | 4.56 | 3.51 | 7.2 | Upgrade
|
| Restricted Cash | - | 0.5 | - | - | - | Upgrade
|
| Other Current Assets | - | - | 1.78 | 4.36 | 2.34 | Upgrade
|
| Total Current Assets | 1,048 | 1,375 | 574.15 | 345.18 | 344.72 | Upgrade
|
| Property, Plant & Equipment | 54.79 | 55.58 | 57.43 | 4.99 | 4.72 | Upgrade
|
| Long-Term Investments | 2 | - | 0.47 | - | 1.01 | Upgrade
|
| Other Long-Term Assets | 21.13 | 3.63 | 3.3 | 2.01 | 0.57 | Upgrade
|
| Total Assets | 1,126 | 1,435 | 635.35 | 352.18 | 351.02 | Upgrade
|
| Accounts Payable | 22.61 | 5.85 | 6.55 | 6.88 | 3.42 | Upgrade
|
| Accrued Expenses | 54.74 | 44.5 | 27.35 | 17.19 | 11.63 | Upgrade
|
| Current Portion of Leases | 6.49 | 7.15 | 4.17 | 1.05 | 0.94 | Upgrade
|
| Current Unearned Revenue | 1.24 | 2.18 | 2.06 | 2.24 | - | Upgrade
|
| Other Current Liabilities | - | - | 3.82 | 0.36 | - | Upgrade
|
| Total Current Liabilities | 85.07 | 59.68 | 43.94 | 27.72 | 16 | Upgrade
|
| Long-Term Leases | 42.05 | 44.57 | 47.56 | 2.02 | 3.07 | Upgrade
|
| Long-Term Unearned Revenue | 3.81 | 4.7 | 4.75 | 6.1 | - | Upgrade
|
| Other Long-Term Liabilities | 3.24 | 0.83 | - | - | 0 | Upgrade
|
| Total Liabilities | 134.17 | 109.79 | 96.25 | 35.85 | 19.07 | Upgrade
|
| Common Stock | 2,408 | 2,276 | 1,192 | 759.43 | 607.58 | Upgrade
|
| Retained Earnings | -1,417 | -952.11 | -653.7 | -439.17 | -275.26 | Upgrade
|
| Comprehensive Income & Other | 1.75 | 0.96 | 0.98 | -3.93 | -0.38 | Upgrade
|
| Total Common Equity | 992.08 | 1,325 | 539.11 | 316.33 | 331.94 | Upgrade
|
| Shareholders' Equity | 992.08 | 1,325 | 539.11 | 316.33 | 331.94 | Upgrade
|
| Total Liabilities & Equity | 1,126 | 1,435 | 635.35 | 352.18 | 351.02 | Upgrade
|
| Total Debt | 48.54 | 51.72 | 51.73 | 3.08 | 4.01 | Upgrade
|
| Net Cash (Debt) | 979.35 | 1,302 | 506.83 | 331.35 | 329.69 | Upgrade
|
| Net Cash Growth | -24.80% | 156.96% | 52.96% | 0.50% | 98.57% | Upgrade
|
| Net Cash Per Share | 10.41 | 16.12 | 8.73 | 6.37 | 8.58 | Upgrade
|
| Filing Date Shares Outstanding | 104.71 | 93.05 | 69.6 | 53.91 | 47.78 | Upgrade
|
| Total Common Shares Outstanding | 95.58 | 92.93 | 68.18 | 53.88 | 47.6 | Upgrade
|
| Working Capital | 963.27 | 1,316 | 530.21 | 317.46 | 328.73 | Upgrade
|
| Book Value Per Share | 10.38 | 14.26 | 7.91 | 5.87 | 6.97 | Upgrade
|
| Tangible Book Value | 992.08 | 1,325 | 539.11 | 316.33 | 331.94 | Upgrade
|
| Tangible Book Value Per Share | 10.38 | 14.26 | 7.91 | 5.87 | 6.97 | Upgrade
|
| Machinery | 12.25 | 7.9 | 6.11 | 4.07 | 2.79 | Upgrade
|
| Leasehold Improvements | 10 | 11.9 | 9.84 | 3.52 | 3.52 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.